Literature DB >> 9015485

Diagnosis and treatment of status epilepticus on a neurological intensive care unit.

M C Walker1, R S Howard, S J Smith, D H Miller, S D Shorvon, N P Hirsch.   

Abstract

Status epilepticus refractory to first-line therapy is associated with a high morbidity and mortality. Correct diagnosis and adequate treatment of this condition require electrographic monitoring and anaesthetic facilities available in specialist intensive care units (ICUs). We carried out an audit of 26 patients admitted to a neurological ICU with a diagnosis of status epilepticus, to identify deficiencies in diagnosis and management prior to transfer to the ICU, and examine the effectiveness of ICU management. Or transfer, only 14 (54%) were in status epilepticus; six were in drug-induced coma or were encephalopathic, and six had pseudostatus epilepticus, of whom four had been intubated. The commonest treatments prior to transfer were benzodiazepines, chlormethiazole and phenytoin; the loading dose of phenytoin was adequate in at least 7/16 cases. All those in status epilepticus on transfer had their seizures successfully controlled, but ten required general anaesthesia with thiopentone, propofol, ketamine or midazolam. Two died--one had a severe encephalitis and the other had had a cardiac arrest prior to treatment. This study highlights deficiencies in the initial diagnosis and management of status epilepticus, the role of specialist neurological intensive care, and the importance of early referral.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9015485     DOI: 10.1093/qjmed/89.12.913

Source DB:  PubMed          Journal:  QJM        ISSN: 1460-2393


  10 in total

Review 1.  Admission to neurological intensive care: who, when, and why?

Authors:  Robin S Howard; Dimitri M Kullmann; Nicholas P Hirsch
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-09       Impact factor: 10.154

Review 2.  Status epilepticus: an evidence based guide.

Authors:  Matthew Walker
Journal:  BMJ       Date:  2005-09-24

3.  Ketamine for Refractory Status Epilepticus: A Systematic Review.

Authors:  Anna Rosati; Salvatore De Masi; Renzo Guerrini
Journal:  CNS Drugs       Date:  2018-11       Impact factor: 5.749

Review 4.  The approach to patients with "non-epileptic seizures".

Authors:  J D C Mellers
Journal:  Postgrad Med J       Date:  2005-08       Impact factor: 2.401

5.  Early ketamine to treat refractory status epilepticus.

Authors:  Andreas H Kramer
Journal:  Neurocrit Care       Date:  2012-04       Impact factor: 3.210

Review 6.  Generalised convulsive status epilepticus: an overview.

Authors:  R Nandhagopal
Journal:  Postgrad Med J       Date:  2006-11       Impact factor: 2.401

Review 7.  NMDA antagonists for refractory seizures.

Authors:  F A Zeiler; J Teitelbaum; L M Gillman; M West
Journal:  Neurocrit Care       Date:  2014-06       Impact factor: 3.210

8.  Pre-hospital and emergency department treatment of convulsive status epilepticus in adults: an evidence synthesis.

Authors:  Moira Cruickshank; Mari Imamura; Corinne Booth; Lorna Aucott; Carl Counsell; Paul Manson; Graham Scotland; Miriam Brazzelli
Journal:  Health Technol Assess       Date:  2022-03       Impact factor: 4.106

Review 9.  Pharmacotherapy for Status Epilepticus.

Authors:  Eugen Trinka; Julia Höfler; Markus Leitinger; Francesco Brigo
Journal:  Drugs       Date:  2015-09       Impact factor: 9.546

10.  (S)-Ketamine in Refractory and Super-Refractory Status Epilepticus: A Retrospective Study.

Authors:  Julia Höfler; Alexandra Rohracher; Gudrun Kalss; Georg Zimmermann; Judith Dobesberger; Georg Pilz; Markus Leitinger; Giorgi Kuchukhidze; Kevin Butz; Alexandra Taylor; Helmut Novak; Eugen Trinka
Journal:  CNS Drugs       Date:  2016-09       Impact factor: 5.749

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.